A diabetic foot ulcer can begin as a small break in the skin. When healing stalls, however, the wound may become a serious threat to mobility, independence and, in severe cases, limb preservation.
PolarityBio is developing a regenerative therapy intended to help close difficult-to-heal wounds. Its lead product, SkinTE, uses a patient’s own skin tissue to create a multicellular biologic. Rather than relying on a single isolated cell type, the approach seeks to preserve a broader mix of skin cells and their surrounding biological structure.
The company’s focus is now sharply defined: Wagner Grade 1 diabetic foot ulcers that have resisted standard treatment. SkinTE remains investigational, but its pivotal clinical programme has reached a major regulatory milestone.
Working with the patient’s own tissue
SkinTE is described by PolarityBio as an autologous cutaneous multicellular therapy. “Autologous” means the tissue comes from the patient who will receive it. The product is prepared from a small sample of healthy skin, processed into a multicellular construct and applied to the wound.
The scientific premise is that skin contains several interacting cell populations, not just one ingredient responsible for repair. PolarityBio’s approach seeks to retain elements of this cellular complexity, with the aim of supporting the wound’s own healing process.
That makes manufacturing and clinical handling important parts of the therapy. The company must process tissue consistently while preserving the characteristics that underpin its proposed regenerative effect. Clinicians also need clear procedures for selecting patients, preparing wounds and applying the product alongside standard care.
SkinTE is not a general-purpose dressing, nor is it approved for routine commercial use. Its availability remains limited to investigational settings, including an expanded-access programme for eligible patients.
The pivotal trial moved the programme forward
PolarityBio’s COVER DFUS II study evaluated SkinTE alongside standard care against standard care alone in patients with non-healing Wagner Grade 1 diabetic foot ulcers. The trial’s primary efficacy measure was complete wound closure within 12 weeks.
In September 2026, the company announced that the U.S. Food and Drug Administration had accepted its Biologics License Application for review and granted Priority Review. The agency set a target action date of March 16, 2027. Acceptance for review is a significant step, but it is not an approval.
At the October 2026 Symposium on Advanced Wound Care, the study’s chair presented topline results. PolarityBio reported that the trial met its primary endpoint. The company also said the results showed improved closure when SkinTE was added to standard care, with additional findings being prepared for peer-reviewed publication.
The detailed data matter. Clinicians and regulators will need to assess the magnitude and durability of wound closure, safety outcomes, patient selection and how the treatment performs in practice. A positive primary endpoint is encouraging, but it does not answer every question about a new biologic.
SkinTE: development snapshot
– Therapy type: Patient-derived multicellular skin biologic.
– Lead indication: Wagner Grade 1 diabetic foot ulcers.
– Pivotal study: COVER DFUS II, a randomized Phase 3 trial.
– Regulatory status: BLA accepted for FDA Priority Review.
– FDA target action date: March 16, 2027.
– Current access: Investigational use, including an expanded-access programme.
Leadership shaped by clinical and operational demands
John Stetson, PolarityBio’s CEO, has experience in finance and company leadership, including earlier roles at PolarityTE, the organisation from which PolarityBio’s history developed. The company’s clinical and scientific leadership includes Nikolai Sopko, MD, PhD, who serves as president, chief operating officer and chief scientific officer, and Ned Swanson, MD, who serves as president and chief medical officer.
Their responsibilities span different but connected challenges. Scientific leadership must maintain the integrity of the therapy and its evidence. Clinical leadership must translate trial findings into treatment protocols. Operational teams must prepare manufacturing, medical affairs and market access capabilities for a potential regulatory decision.
That preparation has become increasingly important as wound-care reimbursement and product classification continue to evolve. If SkinTE receives approval, the company will still need to demonstrate that clinicians can use it reliably and that healthcare systems can evaluate its value.
Beyond a single wound category
PolarityBio is also exploring SkinTE for other chronic wounds, including venous leg ulcers and pressure injuries. These conditions share the challenge of persistent tissue damage, but they differ in underlying causes, patient populations and care pathways. Evidence from diabetic foot ulcers cannot automatically be applied to them.
For now, the company’s immediate task is to support the FDA review and prepare for the next stage without treating regulatory progress as a foregone conclusion. The agency’s decision will depend on its assessment of the submitted evidence, manufacturing controls and benefit-risk profile.
Chronic wounds demand sustained care, and no regenerative product can eliminate the need for proper wound management. Yet a therapy that improves the likelihood of closure could become a meaningful addition for patients whose ulcers have not responded adequately to existing approaches.
PolarityBio’s next chapter will be determined by the quality of its clinical evidence and the FDA’s review. SkinTE has advanced from an experimental tissue construct to a late-stage investigational biologic. Whether it becomes an approved treatment will depend on what the full evidence demonstrates.
